

Supporting Information

Synthesis of Acylguanidine Zanamivir Derivatives as Neuraminidase Inhibitors and Evaluation of Their Bio-activities

Chien-Hung Lin, Tsung-Che Chang, Anindya Das, Ming-Yu Fang, Hui-Chen Hung,
Kai-Cheng Hsu, Jinn-Moon Yang, Mark von Itzstein, Kwok Kong T. Mong, Tsu-An
Hsu,* Chun-Cheng Lin*

Table of Contents:

Materials.....	S2
General Measurements.....	S2
Table S1. Several conditions for cleavage ester bond	S3
General procedure for compounds 3a-3ac synthesis.....	S3
General procedure for compounds 14ad-14af synthesis.....	S4
Assignments of compounds 3a-3ac and compounds 14ad-14af	S5
HPLC of compounds 3j and compounds 14ad	S22
Neuraminidase inhibition assay.....	S22
Reference.....	S23
NMR spectra of all compounds.....	S24


Materials.

Dichloromethane (DCM, Merck), acetonitrile (CH₃CN, Merck), tetrahydrofuran (THF, Merck), ethanol (EtOH, Merck), trifluoroacetic acid (TFA, Acros), sodium hydride (NaH, Acros), triethyl amine (NEt₃, Merck), diisopropylamine (DiPEA, Merck), *N*-(3-dimethylaminopropyl)-*N*'-ethylcarbonate (EDC, Merck), di-*tert*-butyl-dicarbonate (Boc₂O, Acros), potassium carbonate (K₂CO₃, Merck), *N*-hydroxysuccinimide (NHS, Aldrich), and tetrabutylammonium thiocyanate ((*n*-Bu)₄NSCN, TCI) were used as received. All of the commercially available reagents were used without further purification. Anhydrous solvents were purchased from Merck and were used as received. Analytical thin-layer chromatography (TLC) and reverse-phase TLC were performed using pre-coated plates (Silica Gel 60 F254 and 60 RP-18F254S, respectively, Merck). Silica gel 60 and C-18 reverse-phase gel (Merck) were used for flash chromatography.

General Measurements.

¹H and ¹³C NMR spectra were recorded using a Bruker AV-400 spectrometer or a Varian MR-400 MHz spectrometer. The proton chemical shifts are reported in parts per million (ppm) relative to the methyl quintuplet at 3.31 ppm for the residual CD₃OD in methanol-d₄. The carbon chemical shifts are reported in parts per million relative to the internal ¹³C signals in CD₃OD-d₄ (49.00 ppm). The purity of the final products was determined using a Grace Vydac analytic HPLC column with solvent A (ddH₂O+0.1% TFA) and solvent B (MeCN) as the eluents. Mass spectra were obtained using an FAB JMS-700 double-focusing mass spectrometer (JEOL, Tokyo, Japan) and an ESI Finnigan LCQ mass spectrometer (Thermo Finnigan, San Jose, CA, USA) in negative or positive mode.

Table 1. Synthesis of the chiral ester 1



	R1	Condition	Temperature&Time	Yield
Entry 1	Me	1. NaOMe / MeOH 2. NaOH / H ₂ O	r.t.,	<40%
Entry 2	Me	LiOH / H ₂ O / MeOH	r.t., 2hr	20~50%
Entry 3	Me	LiOH / H ₂ O / MeOH	r.t., 12hr	30~60%
Entry 4	Me	NaOH / H ₂ O / MeOH	0°C, 20min	35~60%
Entry 5	Me	Lil / Pyr.	reflux, 12hr	N.R. ^a
Entry 6	Et	NaOH / H ₂ O / MeOH	r.t., 2hr	<60%
Entry 7	Et	LiOH / H ₂ O / MeOH	0°C, 20min	<70%
Entry 8	Et	K ₂ CO ₃ / EtOH	r.t., 2hr	70~90%

^a means that no reaction

General procedure for the synthesis of compound 1

Compound 1 was synthesized using a modification of the procedures reported in the literature. A solution of 1H-pyrazole-1-carboxamide 1 (2.0 g, 13.62 mmol) and Boc₂O (4.30 g, 27.24 mmol) in anhydrous DMF (30 ml) and DCM (30 ml) was added to Et₃N (3.77 ml, 13.62 mmol) at 4 °C.² The resulting solution was stirred at room temperature under N₂ for 8 h. The solvent was evaporated after the completion of the reaction, as monitored by TLC, and the product was purified by column chromatography (hexane/EtOAc 4/1, R_f = 0.25) to give 1H-pyrazole-N-Boc-1-carboxamide (3.06 g, 91%). NaH (48 mg, 1.21 mmol) was added to a solution of the above pure product (200 mg, 0.81 mmol) in anhydrous THF (8 ml, 0.1 M) at 4 °C, and the resulting solution was stirred at 4 °C for 0.5 h, followed


by the addition of the activated acid (0.97 mmol). The reaction was stirred at 4 °C for 4 h, quenched by adding MeOH and then concentrated. The desired isomers were purified by column chromatography (hexane/EtOAc 4/1, R_f = 0.10–0.25) to give isomer **1** (yield 40%–60%). Et₃N (0.035 mL, 0.25 mmol) was added to a stirred solution of isomer **1** (0.25 mmol) and compound **2** (100 mg, 0.23 mmol) in DCM (3 mL), and the resulting solution was stirred at room temperature for 6 h. Then, 10% hydrochloride solution was added, and the mixture was extracted with EA. The combined organic layer was washed with brine, dried over MgSO₄, and concentrated. The residue was purified by column chromatography using silica gel (hexane/EtOAc 1/1, R_f = 0.10–0.25) to give isomer **2** (yield 75%–87%). A solution of TFA (1 mL) in 3 mL of DCM was added to isomer **2** (0.2 mmol) at 0 °C. The reaction was stirred at room temperature for 2 h. After the removal of the solvent, the product was purified using silica gel chromatography (MeOH/DCM 1/9, R_f = 0.15–0.35) to give compound **3** (yield >95%) as a white syrup. To a mixture of compound **3** (0.1 mmol) in EtOH (0.01 M) at 0 °C was added dropwise an aqueous solution of potassium carbonate (0.04 M). The solution was stirred for 30 min in an ice bath. The mixture was then neutralized with IR120 and concentrated under reduced pressure. The residue was purified by column chromatography (H₂O (with 0.1% TFA)/MeCN (7/3), R_f = 0.21–0.60) using C-18 reverse-phase gel to give compound **4** (yield 70%–90%).

General procedure for the synthesis of compounds **3** and **4**

Compounds **3** and **4** were synthesized using a modification of the reported procedures. To a solution of compound **1** (0.51 mmol) in DMF (5 mL) was added EDC (176 mg, 0.92 mmol), DIPEA (0.16 mL, 0.92 mmol), and amine compound **2** (200 mg, 0.46 mmol). The mixture was stirred at room temperature overnight. After the DMF was removed, the mixture was purified by silica gel chromatography


(hexane/EtOAc 4/1, R_f 0.15/0.20) to give compound **18** (yield 65%/83%) as a pale yellow syrup. The Pbf-protecting group in compound **18** (0.2 mmol) was removed by treatment with 4 mL of TFA/DCM (1/3) for 2 h. After the removal of the solvent, the product was purified using silica gel chromatography (MeOH/DCM 1/9, R_f 0.15/0.35) to give compound **19** (yield 70%/83%) as a white syrup. An aqueous solution of potassium carbonate was added dropwise to a solution of compound **19** (0.1 mmol) in EtOH (0.001 M) at 0 °C, and the resulting mixture was stirred for 30 min in an ice bath. The mixture was neutralized with IR120 and dried under vacuum. The residue was purified by column chromatography (H₂O (with 0.1% TFA)/MeCN 7/3, R_f 0.49/0.65) using C-18 reverse-phase gel to give compound **20** (yield 73%/88%).

Assignments of chemical shifts




19 **etami** **an** **r** **N** **en** **luani** **in** **trice** **er** **a**
la **n** **n** **en** **ni** **a** **a**

R_f 0.48 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 2.02 (s, 3H), 3.67-3.74 (m, 2H), 3.80 (dd, J 3.2, 11.2 Hz, 1H), 3.83-3.88 (m, 1H), 4.39 (dd, J 7.2, 8.8 Hz, 1H), 4.52 (dd, J 3.6, 8.8 Hz, 1H), 4.74 (dd, J 2.4, 7.6 Hz, 1H), 5.90 (d, J 2.4 Hz, 1H), 7.56 (d, J 8.0 Hz, 2H), 7.69 (d, J 8.0 Hz, 1H), 7.99 (d, J 8.0 Hz, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.63, 30.67, 51.57, 64.69, 70.49, 71.62, 77.39, 104.09, 129.36, 130.05, 132.82, 135.16, 149.75, 156.24, 163.23, 169.97, 174.55 \square HRMS (ESI-TOF) calcd for C₁₉H₂₅N₄O₈ \square M + H⁺ \square 437.1672, found \square 437.1675.




tert-butyl 2-acetamido-2-deoxy-3-O-(4-tert-butylbenzoyl)-D-glucopyranoside

R_f 0.53 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.35 (s, 9H), 2.02 (s, 3H), 3.67-3.74 (m, 2H), 3.80-3.90 (m, 2H), 4.38 (dd, J 7.6, 8.0 Hz, 1H), 4.52 (dd, J 3.6, 8.4 Hz, 1H), 4.69-4.71 (br, 1H), δ 5.94 (d, J 2.8 Hz, 1H), 7.61 (d, J 8.4 Hz, 2H), 7.93 (d, J 8.4 Hz, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.63, 31.36, 36.10, 51.34, 64.68, 70.60, 71.53, 77.43, 105.50, 127.11, 129.32, 129.59, 148.31, 156.15, 159.43, 165.98, 169.58, 174.58 HRMS (ESI-TOF) calcd for C₃₀H₄₁N₄O₁₁ [M + H]⁺ 493.2298, found 493.2312.




tert-butyl 2-acetamido-2-deoxy-3-O-(4-nitrobenzoyl)-D-glucopyranoside

R_f 0.43 (EA/MeOH/H₂O 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 2.02 (s, 3H), 3.69 (dd, J 5.2, 11.6 Hz, 1H), 3.72-3.74 (m, 1H), 3.81 (dd, J 3.2, 11.6 Hz, 1H), 3.85-3.88 (m, 1H), 4.35-4.38 (br, 1H), 4.53-4.55 (m, 1H), 4.67-4.69 (br, 1H), 5.90 (d, J 3.2 Hz, 1H), 8.20 (d, J 8.0 Hz, 2H), 8.40 (d, J 8.0 Hz, 1H) ¹³C NMR (100 MHz, CD₃OD) δ 22.74, 30.70, 51.57, 64.77, 70.05, 71.62, 77.62, 107.79, 124.01, 131.13, 145.83, 150.90, 163.18, 168.69, 174.34, 176.13 HRMS (FAB) calcd for C₁₉H₂₄N₅O₁₀ [M + H]⁺ 482.1523, found 482.1529.




1-(4-(dimethylamino)phenyl)-N-(2-acetyl-2-(hydroxymethyl)-4-hydroxy-5-(hydroxymethyl)oxolan-5-yl)guanidine trifluoroacetate

R_f = 0.43 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.94 (s, 3H), 3.07 (s, 6H), 3.63-3.70 (m, 2H), 3.81 (dd, J = 2.4, 11.6 Hz, 1H), 3.90-3.94 (m, 1H), 4.33-4.35 (m, 2H), 5.02 (br, 1H), 5.92 (d, J = 2.0 Hz, 1H), 6.89 (d, J = 8.8 Hz, 2H), 7.76 (d, J = 8.8 Hz, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.62, 40.24, 62.83, 64.83, 67.30, 69.95, 71.23, 78.41, 111.83, 112.16, 121.56, 129.95, 146.09, 154.33, 165.52, 170.79, 174.60 ¹H NMR (FAB) calcd for C₁₉H₂₄N₅O₁₀ [M + H]⁺ = 482.1523, found = 482.1529.




1-(4-phenylpiperazin-1-yl)-N-(2-acetyl-2-(hydroxymethyl)-4-hydroxy-5-(hydroxymethyl)oxolan-5-yl)guanidine trifluoroacetate

R_f = 0.47 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.98 (s, 3H), 3.68-3.72 (m, 2H), 3.79 (s, 2H), 3.80 (dd, J = 3.2, 11.2 Hz, 1H), 3.85-3.89 (m, 1H), 4.39 (dd, J = 8.4, 8.8 Hz, 1H), 4.47 (dd, J = 3.6, 8.8 Hz, 1H), 4.74 (dd, J = 2.4, 8.4 Hz, 1H), 5.90 (d, J = 2.4 Hz, 1H), 7.25-7.28 (m, 1H), 7.29-7.31 (m, 4H) ¹³C NMR (100 MHz, CD₃OD) δ 22.59, 44.34, 51.15, 64.48, 70.18, 71.53, 77.62, 106.66, 119.44, 128.49, 129.68, 130.55, 134.15, 147.29, 155.72, 165.36, 174.51, 175.27 ¹H NMR (MALDI) calcd for C₂₀H₂₆N₄O₈ [M + H]⁺ = 451.1751, found = 451.1739.




1 **etami** **an** **r** **N** **na** **t** **alen** **la** **et** **uani** **in** **tri**
er **ala** **t** **n** **n** **en** **ni** **a** **i**

R_f \square 0.55 (EA MeOH:H₂O, 3:2) ^1H NMR (400 MHz, CD₃OD) δ 1.98 (s, 3H), 3.65-3.70 (m, 2H), 3.80 (dd, J \square 3.2, 11.2 Hz, 1H), 3.81-3.86 (m, 1H), 3.97 (s, 2H), 4.28 (dd, J \square 8.4, 8.8 Hz, 1H), 4.49 (dd, J \square 3.2, 8.8 Hz, 1H), 4.74 (dd, J \square 2.8, 8.0 Hz, 1H), 5.90 (d, J \square 2.8 Hz, 1H), 7.43 (dd, J \square 1.2, 8.4 Hz, 1H), 7.45-7.50 (m, 2H), 7.80 (s, 1H), 7.82-7.84 (m, 3H) ^{13}C NMR (100 MHz, CD₃OD) δ 22.46, 44.61, 50.82, 64.70, 70.98, 71.35, 77.25, 106.03, 127.16, 127.38, 128.29, 128.65, 128.69, 129.42, 129.54, 131.52, 134.14, 134.92, 147.43, 155.50, 164.99, 174.47, 174.82 \square HRMS (MALDI) calcd for C₂₀H₂₆N₄O₈ \square M + H $^+$ \square 451.1751, found \square 451.1739.




2 **etami** **an** **r** **N** **na** **t** **alen** **la** **et** **uani** **in** **tri**
er **ala** **t** **n** **n** **en** **ni** **a** **i**

R_f \square 0.55 (EA MeOH:H₂O, 3:2) ^1H NMR (400 MHz, CD₃OD) δ 1.97 (s, 3H), 3.65-3.69 (m, 2H), 3.79 (dd, J \square 3.2, 11.2 Hz, 1H), 3.81-3.86 (m, 1H), 3.97 (s, 2H), 4.28 (dd, J \square 7.6, 8.0 Hz, 1H), 4.29 (s, 2H), 4.49 (dd, J \square 0.8, 7.6 Hz, 1H), 4.77 (dd, J \square 2.8, 6.8 Hz, 1H), 5.90 (d, J \square 2.8 Hz, 1H), 7.44-7.49 (m, 2H), 7.51-7.57 (m, 2H), 7.86 (dd, J \square 2.8, 6.8 Hz, 1H), 7.90 (d, J \square 7.6 Hz, 1H), 7.98 (d, J \square 8.0 Hz, 1H) ^{13}C NMR (100 MHz, CD₃OD) δ 22.49, 42.18, 50.82, 64.71, 70.92, 71.35, 77.31, 106.20, 124.72, 126.57, 127.04, 127.65, 129.69, 129.71, 129.83, 130.29, 133.50, 135.40, 147.30, 155.46, 164.88, 174.47, 174.78 \square HRMS (MALDI) calcd for C₂₀H₂₆N₄O₈ \square M + H $^+$ \square 451.1751, found \square 451.1743.




1-(2-(4-methoxyphenyl)acetamido)-3,4,6-tri-O-acetyl-β-D-glucopyranoside

R_f 0.42 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 2.00 (s, 3H), 3.66-3.73 (m, 2H), 3.76 (s, 2H), 3.78-3.88 (m, 2H), 3.82 (s, 3H), 4.30 (dd, J 8.4, 8.8 Hz, 1H), 4.48 (dd, J 0.8, 8.4 Hz, 1H), 4.74 (dd, J 2.0, 7.2 Hz, 1H), 5.90 (d, J 2.8 Hz, 1H), 6.93 (dd, J 7.2, 7.6 Hz, 1H), 6.98 (d, J 8.4 Hz, 1H), 7.20 (d, J 7.6 Hz, 1H), 7.30 (dd, J 7.2, 8.4 Hz, 1H) ¹³C NMR (100 MHz, CD₃OD) δ 22.61, 39.67, 51.36, 55.99, 61.54, 64.10, 69.64, 72.09, 77.52, 105.55, 111.68, 121.67, 122.75, 130.31, 132.42, 155.69, 158.95, 162.97, 173.12, 174.31, 175.2760 HRMS (MALDI) calcd for C₂₁H₂₈N₄O₉ [M + H]⁺ 480.1856, found 480.1850




1-(2-(1-naphthyl)acetamido)-3,4,6-tri-O-acetyl-β-D-glucopyranoside

R_f 0.53 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.97 (s, 3H), 1.97 (br, 2H), 3.15 (t, J 7.6 Hz, 1H), 3.66-3.70 (m, 2H), 3.80 (dd, J 3.2, 11.2 Hz, 1H), 3.81-3.85 (m, 1H), 4.28 (br, 1H), 4.49 (dd, J 0.8, 8.0 Hz, 1H), 4.52 (br, 1H), 5.87 (d, J 3.2 Hz, 1H), 7.37 (m, 3H), 7.70 (s, 1H), 7.78 (m, 3H) ¹³C NMR (100 MHz, CD₃OD) δ 22.48, 31.26, 39.54, 39.65, 50.77, 64.72, 71.15, 71.34, 77.19, 106.02, 126.57, 127.15, 127.68, 127.92, 128.50, 128.61, 129.25, 133.75, 135.09, 138.79, 147.43, 155.28, 164.99, 174.48, 176.07 HRMS (ESI-TOF) calcd for C₂₅H₃₀N₄O₈ [M + H]⁺ 514.2064, found 514.2060.




2,3,4,6-Tetra-O-acetyl-2-amino-2-deoxy-D-glucopyranose 1-thio-(1 β -naphthalenyl)thiourea

R_f \square 0.51 (EA/MeOH/H₂O, 3/2/1) 1H NMR (400 MHz, CD₃OD) δ 1.92 (s, 3H), 3.65-3.69 (m, 2H), 3.80 (dd, J \square 2.8, 11.2 Hz, 1H), 3.80-3.85 (m, 1H), 3.96 (s, 2H), 4.28 (br, 1H), 4.47 (dd, J \square 0.8, 8.4 Hz, 1H), 4.57 (br, 1H), 5.87 (d, J \square 2.4 Hz, 1H), 7.45-7.51 (m, 3H), 7.79-7.83 (m, 3H), 7.92 (s, 1H) ^{13}C NMR (100 MHz, CD₃OD) δ 22.47, 39.70, 50.95, 64.71, 70.80, 71.33, 77.33, 106.23, 127.55, 127.90, 128.42, 128.75, 129.97, 132.38, 133.84, 135.12, 147.28, 155.34, 164.89, 172.78, 174.46 HRMS (ESI-TOF) calcd for C₂₄H₂₈N₄O₈S $[M + H]^+$ \square 533.1706 , found \square 533.1713.




2,3,4,6-Tetra-O-acetyl-2-amino-2-deoxy-D-glucopyranose 1-thio-(1 β -decalinyl)thiourea

R_f \square 0.57 (EA/MeOH/H₂O, 3/2/1) 1H NMR (400 MHz, CD₃OD) δ 1.68 (m, 10H), 1.75 (m, 3H), 1.97 (m, 2H), 2.00 (s, 3H), 2.19 (s, 2H), 3.68-3.72 (m, 2H), 3.80 (dd, J \square 3.2, 11.2 Hz, 1H), 3.85-3.89 (m, 1H), 4.34 (dd, J \square 8.4, 8.8 Hz, 1H), 4.49 (dd, J \square 3.6, 8.8 Hz, 1H), 4.62 (dd, J \square 2.4, 8.4 Hz, 1H), 5.92 (d, J \square 2.4 Hz, 1H) ^{13}C NMR (100 MHz, CD₃OD) δ 22.56, 30.06, 34.68, 37.67, 43.27, 50.96, 52.11, 64.69, 70.65, 71.38, 77.47, 106.55, 147.26, 155.36, 165.03, 174.40, 175.13 \square HRMS (ESI-TOF) calcd for C₂₀H₂₆N₄O₈ $[M + H]^+$ \square 509.2611 , found \square 509.2615




2-(3-(2-(2,3,4-trihydroxy-5-(carboxymethyl)-2H-pyridin-5-yl)propyl)phenyl)acetamide

R_f 0.49 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.99 (s, 3H), 2.80 (t, J 8.0 Hz, 2H), 2.95 (t, J 8.0 Hz, 2H), 3.67-3.70 (m, 2H), 3.80 (dd, J 2.8, 11.6 Hz, 1H), 3.83-3.88 (m, 1H), 4.29 (dd, J 7.2, 8.4 Hz, 1H), 4.45 (dd, J 1.2, 8.4 Hz, 1H), 4.56 (dd, J 2.8, 7.2 Hz, 1H), 5.90 (d, J 2.8 Hz, 1H), 7.16-7.29 (m, 5H) ¹³C NMR (100 MHz, CD₃OD) δ 22.57, 31.23, 39.65, 50.91, 64.73, 70.92, 71.46, 77.39, 106.04, 127.48, 129.40, 129.60, 132.82, 141.30, 147.60, 155.38, 165.20, 174.49, 176.18 HRMS (MALDI) calcd for C₂₁H₂₈N₄O₈ $[M + H]^+$ 465.1907, found 465.1925.




2-(3-(2-(2,3,4-trihydroxy-5-(carboxymethyl)-2H-pyridin-5-yl)propyl)phenyl)ethanesulfonamide

R_f 0.45 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.98 (s, 3H), 3.67-3.70 (m, 2H), 3.81 (dd, J 2.8, 11.6 Hz, 1H), 3.83-3.88 (m, 3H), 4.28 (dd, J 7.2, 8.4 Hz, 1H), 4.49 (dd, J 0.8, 8.0 Hz, 1H), 4.56 (dd, J 2.4, 7.2 Hz, 1H), 5.89 (d, J 3.2 Hz, 1H), 7.28 (dd, J 1.2, 7.2 Hz, 1H), 7.34 (dd, J 1.2, 7.2 Hz, 2H), 7.45 (d, J 7.2 Hz, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.29, 39.71, 39.65, 50.66, 64.50, 70.77, 71.10, 77.06, 105.89, 128.50, 130.419, 131.34, 134.79, 147.13, 155.10, 164.66, 172.49, 174.26 HRMS (ESI-TOF) calcd for C₂₀H₂₆N₄O₈S $[M + H]^+$ 483.1550, found 483.1552.




2-acetyl-3-(2-hydroxy-3-(hydroxymethyl)-4-hydroxybut-3-en-1-yl)-5-hydroxy-2,3-dihydro-4H-pyridin-4-one

R_f 0.52 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 2.00 (s, 3H), 2.33 (s, 3H), 2.80 (br, 2H), 2.98 (t, J 8.0 Hz, 2H), 3.67-3.70 (m, 2H), 3.80 (dd, J 3.2, 11.2 Hz, 1H), 3.83-3.88 (m, 1H), 4.29 (br, 1H), 4.50 (dd, J 1.2, 8.0 Hz, 1H), 4.55 (dd, J 2.8, 7.2 Hz, 1H), 5.90 (d, J 3.2 Hz, 1H), 7.16-7.29 (m, 4H) ¹³C NMR (100 MHz, CD₃OD) δ 19.28, 22.52, 28.41, 30.85, 38.36, 50.91, 64.68, 70.92, 71.37, 77.20, 105.75, 127.21, 127.67, 129.40, 129.69, 131.37, 137.09, 139.24, 147.75, 155.33, 165.38, 174.47, 176.23 HRMS (ESI-TOF) calcd for C₂₂H₃₀N₄O₈ [M + H]⁺ 478.2064, found 478.2055.




2-acetyl-3-(2-hydroxy-3-(hydroxymethyl)-4-hydroxybut-3-en-1-yl)-5-methoxy-2,3-dihydro-4H-pyridin-4-one

R_f 0.48 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) 1.99 (s, 3H), 2.77 (t, J 8.0 Hz, 2H), 2.95 (t, J 8.0 Hz, 2H), 3.67-3.70 (m, 2H), 3.77-3.83 (m, 6H), 4.25 (dd, J 7.2, 8.4 Hz, 1H), 4.40 (dd, J 1.2, 8.4 Hz, 1H), 4.52 (dd, J 2.8, 7.2 Hz, 1H), 5.75 (d, J 2.8 Hz, 1H), 6.80 (dd, J 7.6, 8.0 Hz, 1H), 6.90 (d, J 8.0 Hz, 1H), 7.10 (d, J 7.6 Hz, 1H), 7.18 (dd, J 7.6, 8.0 Hz, 1H) ¹³C NMR (100 MHz, CD₃OD) δ 22.63, 26.46, 38.07, 54.57, 55.74, 64.57, 70.40, 71.65, 77.32, 104.68, 111.47, 121.55, 129.05, 129.12, 131.05, 155.53, 158.86, 174.43, 176.81 HRMS (ESI-TOF) calcd for C₂₁H₂₈N₄O₈ [M + H]⁺ 495.2091, found 495.2094.




2-bromo-N-(2-hydroxy-3-(hydroxymethyl)-4-(2-oxo-2-(3-bromophenyl)propylamino)but-3-en-1-yl)furan-2-carboxamide triethylalaninate

R_f = 0.45 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 2.00 (s, 3H), 2.81 (t, J = 7.6 Hz, 2H), 3.11 (t, J = 7.6 Hz, 2H), 3.65-3.70 (m, 2H), 3.80 (dd, J = 2.8, 11.6 Hz, 1H), 3.83-3.88 (m, 1H), 4.28 (dd, J = 7.2, 8.4 Hz, 1H), 4.50 (dd, J = 1.2, 8.4 Hz, 1H), 4.60 (dd, J = 2.8, 7.2 Hz, 1H), 5.90 (d, J = 2.8 Hz, 1H), 7.13 (dt, J = 2.0, 8.0 Hz, 1H), 7.28 (dt, J = 2.0, 8.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H) ¹³C NMR (100 MHz, CD₃OD) δ 22.52, 31.41, 37.75, 50.78, 64.72, 71.06, 71.35, 77.23, 106.11, 125.11, 128.99, 129.60, 131.86, 134.00, 140.45, 147.41, 155.30, 164.98, 174.49, 175.64 HRMS (ESI-TOF) calcd for C₂₁H₂₈N₄O₈ [M + H]⁺ = 543.1091, found = 543.1082.




2-(trifluoromethyl)-N-(2-hydroxy-3-(hydroxymethyl)-4-(2-oxo-2-(3-(trifluoromethyl)phenyl)propylamino)but-3-en-1-yl)furan-2-carboxamide triethylalaninate

R_f = 0.39 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.99 (s, 3H), 2.80 (t, J = 7.6 Hz, 2H), 3.14 (t, J = 7.6 Hz, 2H), 3.65-3.70 (m, 2H), 3.80 (dd, J = 2.0, 3.2 Hz, 1H), 3.83-3.88 (m, 1H), 4.32 (dd, J = 8.0, 8.4 Hz, 1H), 4.47 (dd, J = 0.8, 8.8 Hz, 1H), 4.66 (dd, J = 2.4, 7.6 Hz, 1H), 5.91 (d, J = 3.2 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H) ¹³C NMR (100 MHz, CD₃OD) δ 22.54, 27.72, 39.28, 50.87, 64.75, 70.88, 71.39, 77.26, 106.11, 127.16, 128.10, 132.42, 133.61, 139.98, 147.49, 155.38, 165.06, 174.55, 176.55 HRMS (ESI-TOF) calcd for C₂₁H₂₈N₄O₈ [M + H]⁺ = 535.1859, found = 535.1855.




2,3,4,6-tetra-O-acetyl-2-amino-1,3,5-triazin-4-ylidene-β-D-galactopyranoside

R_f 0.21 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.99 (s, 3H), 2.84 (br, 2H), 3.03 (t, J 7.6 Hz, 2H), 3.66-3.70 (m, 2H), 3.81 (dd, J 2.8, 11.6 Hz, 1H), 3.84-3.86 (m, 1H), 4.30 (br, 1H), 4.50 (dd, J 1.2, 7.6 Hz, 1H), 4.57 (dd, J 2.8, 7.6 Hz, 1H), 5.89 (d, J 2.8 Hz, 1H), 7.31 (d, J 8.4 Hz, 2H), 7.43 (d, J 8.4 Hz, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.37, 30.24, 31.14, 36.07, 38.98, 50.55, 64.56, 70.89, 71.22, 71.46, 77.19, 105.98, 123.67, 131.06, 131.13, 142.06, 147.30, 155.25, 164.87, 174.30, 175.79 HRMS (ESI-TOF) calcd for C₂₁H₂₉N₅O₈ [M + H]⁺ 479.2016, found 479.2007.




2,3,4,6-tetra-O-acetyl-2-(tetrahydrofuran-2-ylidene)-β-D-galactopyranoside

R_f 0.51 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.52-1.60 (m, 1H), 1.71-1.78 (m, 2H), 1.99 (s, 3H), 2.05-2.13 (m, 1H), 2.21-2.28 (m, 1H), 2.52 (br, 2H), 3.37 (dd, J 6.8, 8.0 Hz, 2H), 3.66-3.90 (m, 7H), 4.30 (dd, J 7.6, 8.0 Hz, 1H), 4.51 (dd, J 1.2, 8.0 Hz, 1H), 4.58 (dd, J 2.8, 7.6 Hz, 1H), 5.92 (d, J 2.8 Hz, 1H) ¹³C NMR (100 MHz, CD₃OD) δ 22.59, 28.60, 32.94, 36.66, 39.79, 51.11, 64.73, 68.81, 70.92, 71.48, 73.87, 77.39, 105.45, 148.30, 155.53, 165.20, 174.44, 176.79 HRMS (ESI-TOF) calcd for C₁₈H₂₈N₄O₉ [M + H]⁺ 444.1856, found 444.1848.




1,2,3,4,6-pentakis-O-acetyl- β -D-glucopyranosyl (1 \rightarrow 3)-N-(E)-1-(3-(2,4-difluorophenyl)acryloyl)guanidinyl-L-alanine triethylammonium salt

R_f 0.29 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 2.02 (s, 3H), 3.70 (dd, J 5.2, 11.2 Hz, 1H), 3.71-3.73 (m, 1H), 3.82 (dd, J 3.2, 11.2 Hz, 1H), 3.86-3.90 (m, 1H), 4.37 (t, J 8.4 Hz, 1H), 4.50-4.51 (m, 1H), 4.72-4.75 (br, 1H), 5.96 (d, J 2.8 Hz, 1H), 6.72 (d, J 15.2 Hz, 1H), 7.33 (td, J 8.4, 18.4 Hz, 1H), 7.48-7.49 (br, 1H), 7.63 (t, J 8.4 Hz, 1H), 7.80 (t, J 15.2 Hz, 1H) ¹³C NMR (100 MHz, CD₃OD) 22.57, 30.67, 51.08, 64.69, 70.68, 71.54, 77.58, 106.44, 117.98, 118.12, 119.03, 119.17, 120.53, 127.11, 132.89, 145.61, 147.44, 156.01, 165.14, 168.23, 174.55 HRMS (FAB) calcd for C₂₁H₂₅N₄O₈F₂ [M + H]⁺ 499.1640, found 499.1630.




1,2,3,4,6-pentakis-O-acetyl- β -D-glucopyranosyl (1 \rightarrow 3)-N-(E)-1-(3-(3,4,5-trimethoxyphenyl)propyl)guanidinyl-L-alanine triethylammonium salt

R_f 0.37 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.99 (s, 3H), 2.79 (t, J 6.8 Hz, 2H), 2.93 (t, J 6.8 Hz, 2H), 3.66-3.70 (m, 2H), 3.72 (s, 3H), 3.79-3.86 (m, 2H), 3.81 (s, 6H), 4.26 (dd, J 7.2, 8.0 Hz, 1H), 4.51 (dd, J 0.8, 8.0 Hz, 1H), 4.56 (dd, J 3.2, 7.2 Hz, 1H), 5.90 (d, J 3.2 Hz, 1H), 6.55 (s, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.52, 31.48, 39.81, 56.60, 61.09, 64.72, 71.08, 71.34, 77.23, 106.20, 106.75, 137.61, 147.33, 150.58, 154.54, 155.30, 164.90, 174.51, 176.15 HRMS (ESI-TOF) calcd for C₂₅H₃₄N₄O₁₁ [M + H]⁺ 568.2381, found 568.2375.




1-(4-amino-1-piperazinyl)butan-3-yl 2-acetamido-3,4,6-tri-O-acetyl- β -D-glucopyranoside

$R_f = 0.33$ (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.94-1.97 (m, 2H), 2.00 (s, 3H), 2.52 (t, $J = 6.0$ Hz, 2H), 2.74 (t, $J = 7.6$ Hz, 2H), 3.66-3.71 (m, 2H), 3.81 (dd, $J = 3.2, 11.6$ Hz, 1H), 3.84-3.87 (m, 1H), 4.31 (dd, $J = 7.6, 8.4$ Hz, 1H), 4.45 (dd, $J = 1.2, 7.6$ Hz, 1H), 4.56 (dd, $J = 2.8, 7.6$ Hz, 1H), 5.92 (d, $J = 2.8$ Hz, 1H), 7.32 (d, $J = 6.4$ Hz, 2H), 7.40 (d, $J = 8.4$ Hz, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.50, 26.75, 35.17, 36.99, 50.96, 64.68, 70.75, 71.33, 77.34, 106.33, 124.02, 129.94, 131.26, 144.15, 147.27, 155.42, 164.89, 174.45, 176.64 HRMS (ESI-TOF) calcd for C₂₂H₃₁N₅O₈ [M + H]⁺ 493.2173, found 493.2171




1-(4-phenoxy-1-piperazinyl)butan-3-yl 2-acetamido-3,4,6-tri-O-acetyl- β -D-glucopyranoside

$R_f = 0.47$ (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.99 (s, 3H), 2.14 (t, $J = 6.0$ Hz, 2H), 1.99 (s, 3H), 2.68 (s, 3H), 3.69 (dd, $J = 5.2, 11.2$ Hz, 1H), 3.70 (dd, $J = 1.2, 8.8$ Hz, 1H), 3.80 (dd, $J = 3.2, 11.2$ Hz, 1H), 3.86 (ddd, $J = 3.2, 5.2, 8.8$ Hz, 1H), 4.04 (d, $J = 6.0$ Hz, 1H), 4.30 (dd, $J = 7.6, 8.4$ Hz, 1H), 4.49 (dd, $J = 1.2, 8.4$ Hz, 1H), 4.62 (dd, $J = 2.8, 7.6$ Hz, 1H), 5.90 (d, $J = 2.8$ Hz, 1H), 6.88-6.91 (m, 3H), 7.24-7.26 (m, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.54, 25.18, 34.71, 50.91, 64.69, 67.59, 71.43, 77.41, 106.35, 115.45, 121.83, 130.45, 147.34, 155.47, 160.12, 164.98, 174.47, 176.77 HRMS (MALDI) calcd for C₂₂H₃₀N₄O₈ [M + H]⁺ 495.2013, found 495.2018.




1,2-O-isopropylidene-3-O-acetyl-4-O-(4-cyclohexylbutyl)-D-glucopyranose

R_f 0.59 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 0.87-0.92 (m, 2H), 1.17-1.27 (m, 6H), 1.37 (quintet, J 6.0 Hz, 2H), 1.63 (quintet, J 7.6 Hz, 2H), 1.67-1.73 (m, 2H), 2.00 (s, 3H), 2.46 (t, J 6.8 Hz, 2H), 3.62-3.71 (m, 2H), 3.81 (dd, J 3.2, 14.4 Hz, 1H), 3.82-3.87 (m, 1H), 4.31 (dd, J 7.6, 8.0 Hz, 1H), 4.50 (dd, J 1.2, 8.0 Hz, 1H), 4.61 (dd, J 2.8, 6.8 Hz, 1H), 5.92 (d, J 2.8 Hz, 1H) ¹³C NMR (100 MHz, CD₃OD) δ 22.51, 25.59, 27.21, 27.44, 27.74, 34.47, 37.86, 38.21, 38.75, 50.85, 64.73, 70.82, 71.35, 77.39, 106.35, 147.23, 155.47, 164.90, 174.49, 176.10 HRMS (ESI-TOF) calcd for C₂₃H₃₈N₄O₈ [M + H]⁺ 498.2690, found 498.2692.




1,2-O-isopropylidene-3-O-acetyl-4-O-(4-phenylbutyl)-D-glucopyranose

R_f 0.56 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.68 (quintet, J 3.6 Hz, 4H), 2.00 (s, 3H), 2.49 (br, 2H), 2.63 (t, J 6.8 Hz, 2H), 3.66-3.70 (m, 2H), 3.81 (dd, J 3.2, 8.4 Hz, 1H), 3.82-3.87 (m, 1H), 4.30 (dd, J 7.6, 8.0 Hz, 1H), 4.50 (dd, J 1.2, 8.0 Hz, 1H), 4.60 (dd, J 2.8, 7.2 Hz, 1H), 5.91 (d, J 3.2 Hz, 1H) ¹³C NMR (100 MHz, CD₃OD) δ 22.51, 24.85, 31.73, 36.43, 37.67, 50.85, 64.73, 70.88, 71.35, 77.35, 106.35, 126.83, 129.34, 129.39, 143.24, 147.29, 155.47, 164.93, 174.49, 176.90 HRMS (ESI-TOF) calcd for C₂₃H₃₂N₄O₈ [M + H]⁺ 492.2220, found 492.2227.




Etamivertin triethylamine salt

R_f 0.53 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.38 (m, 2H), δ 1.66 (m, 4H), 1.99 (s, 3H), 2.46 (t, J 6.0 Hz, 2H), 2.61 (t, J 7.6 Hz, 2H), 3.66-3.70 (m, 2H), 3.81 (dd, J 2.8, 11.6 Hz, 1H), 3.82-3.87 (m, 1H), 4.29 (dd, J 7.6, 8.4 Hz, 1H), 4.49 (dd, J 1.2, 8.4 Hz, 1H), 4.58 (dd, J 3.2, 7.2 Hz, 1H), 5.89 (d, J 3.2 Hz, 1H), 7.11-7.17 (m, 3H), 7.22-7.25 (m, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.52, 25.11, 29.45, 32.27, 36.59, 37.76, 50.91, 64.69, 70.85, 71.37, 77.28, 105.99, 126.71, 129.28, 129.38, 132.82, 143.61, 147.60, 155.43, 165.30, 174.49, 176.98 HRMS (ESI-TOF) calcd for C₂₄H₃₄N₄O₈ [M + H]⁺ 506.2377, found 506.2385.




Etamivertin triethylamine salt

R_f 0.49 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 0.91 (dd, J 7.2, 7.6 Hz, 1H), 1.15 (d, J 6.8 Hz, 1H), 1.47 (ddq, J 6.8, 7.2, 14.4 Hz, 1H), 1.47 (ddq, J 6.8, 7.6, 14.4 Hz, 1H), 1.97 (s, 3H), 2.46-2.48 (br, 1H), 3.68 (dd, J 5.2, 11.6 Hz, 1H), 3.69-3.71 (m, 1H), 3.82 (dd, J 3.2, 11.6 Hz, 1H), 3.85-3.88 (m, 1H), 4.32 (dd, J 8.4, 8.4 Hz, 1H), 4.48-4.50 (m, 1H), 4.64-4.67 (br, 1H), 5.90 (d, J 2.8 Hz, 1H) ¹³C NMR (100 MHz, CD₃OD) δ 11.67, 16.63, 16.70, 22.59, 27.54, 44.44, 51.09, 64.69, 70.62, 71.47, 77.51, 106.22, 147.64, 155.75, 165.38, 174.46, 180.70 HRMS (FAB) calcd for C₁₇H₂₉N₄O₈ [M + H]⁺ 417.1985, found 417.1980.




1 **etami** **an** **r** **N** **imet** **ten** **uani** **in** **fric**
l **er** **alaf** **n** **n** **en** **ni** **a** **i** **a**

R_f 0.52 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 0.99 (d, J 6.4 Hz, 3H), 1.17 (s, 6H), 1.23-1.26 (m, 1H), 1.33-1.44 (m, 5H), 2.00 (s, 3H), 2.28 (dd, J 6.0, 12.8 Hz), 2.48 (dd, J 4.0, 14.4 Hz, 1H), 3.68 (dd, J 5.2, 11.2 Hz, 1H), 3.69-3.72 (m, 1H), 3.81 (dd, J 3.2, 11.2 Hz, 1H), 3.83-3.87 (m, 1H), 4.30 (dd, J 7.6, 7.6 Hz, 1H), 4.51 (dd, J 3.6, 8.0 Hz, 1H), 4.60 (dd, J 3.2, 7.6 Hz, 1H), 5.92 (d, J 3.2 Hz, 1H) ¹³C NMR (100 MHz, CD₃OD) δ 19.85, 22.56, 22.64, 29.16, 29.24, 31.25, 38.25, 44.74, 45.35, 51.02, 64.75, 70.96, 71.36, 71.47, 77.26, 105.14, 148.45, 155.43, 166.01, 174.41, 176.57 HRMS (FAB) calcd for C₂₂H₃₇N₄O₈ [M + H]⁺ 485.2611, found 485.2601.




2 **etami** **an** **r** **N** **en** **un** **e** **an** **uani** **in** **fric**
l **er** **alaf** **n** **n** **en** **ni** **a** **i** **a**

R_f 0.57 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.32 (m, 10H), 1.44 (quintet, J 6.8 Hz, 2H), 1.64 (quintet, J 6.8 Hz, 2H), 1.74 (quintet, J 6.8 Hz, 2H), 2.00 (s, 3H), 2.48 (t, J 7.2 Hz, 2H), 3.71-3.75 (m, 2H), 3.81 (dd, J 3.2, 11.6 Hz, 1H), 3.86-3.96 (m, 4H), 4.36 (dd, J 8.8, 9.2 Hz, 1H), 4.46 (dd, J 0.8, 9.2 Hz, 1H), 4.72 (dd, J 3.2, 6.8 Hz, 1H), 5.93 (d, J 3.2 Hz, 1H), 6.85-6.88 (m, 3H), 7.20 (dd, J 7.6, 8.0 Hz, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.33, 25.08, 26.92, 29.75, 30.11, 30.18, 30.22, 30.37, 37.63, 50.81, 64.44, 68.58, 70.51, 71.23, 77.03, 105.09, 115.24, 121.24, 130.15, 148.11, 155.25, 160.32, 165.86, 174.21, 176.87 HRMS (ESI-TOF) calcd for C₂₉H₄₄N₄O₉ [M + H]⁺ 592.3108, found 592.3102.




Etamivanor N-enantiomer triethyl
lactate sodium salt

R_f 0.49 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.99 (s, 3H), 3.16 (t, J 6.4 Hz, 2H), 3.43 (t, J 6.4 Hz, 2H), 3.64-3.69 (m, 2H), 3.81 (dd, J 3.2, 11.2 Hz, 1H), 3.82-3.88 (m, 1H), 4.22 (t, J 7.6 Hz, 1H), 4.38-4.41 (m, 2H), 5.86 (d, J 2.8 Hz, 1H), 7.24 (m, 1H), 7.33 (m, 2H), 7.42 (m, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.67, 33.81, 41.92, 51.70, 64.70, 70.42, 71.26, 77.66, 108.22, 127.95, 130.33, 131.21, 136.07, 146.39, 157.67, 165.26, 174.28 HRMS (ESI-TOF) calcd for C₂₀H₂₈N₄O₇S [M + H]⁺ 468.1679, found 468.1671.



Etamivanor N-natalenolactate sodium salt

R_f 0.65 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.96 (s, 3H), 3.06 (t, J 7.2 Hz, 2H), 3.59 (t, J 7.2 Hz, 2H), 3.64-3.69 (m, 2H), 3.81 (dd, J 2.8, 11.2 Hz, 1H), 3.83-3.88 (m, 1H), 4.20 (br, 1H), 4.37-4.39 (m, 2H), 5.78 (d, J 2.8 Hz, 1H), 7.40-7.48 (m, 3H), 7.73 (s, 1H), 7.83 (m, 3H) ¹³C NMR (100 MHz, CD₃OD) δ 22.63, 36.08, 43.86, 51.53, 64.72, 70.42, 71.26, 77.67, 108.50, 126.74, 127.27, 128.11, 128.47, 128.56, 128.67, 129.43, 133.91, 135.08, 136.76, 146.69, 157.60, 165.10, 174.48 HRMS (ESI-TOF) calcd for C₂₄H₃₀N₄O₇ [M + H]⁺ 486.2114, found 486.2117.



16b-258

R_f 0.52 (EA/MeOH/H₂O, 3/2/1) ¹H NMR (400 MHz, CD₃OD) δ 1.97 (s, 3H), 3.66 (dd, J 1.2, 11.2 Hz, 1H), 3.80 (dd, J 3.2, 11.2 Hz, 1H), 3.68 (dd, J 5.2, 7.2 Hz, 1H), 3.85-3.89 (m, 1H), 4.26 (dd, J 8.4, 9.6 Hz, 1H), 4.41 (dd, J 1.2, 9.6 Hz, 1H), 4.42-4.45 (m, 2H), 4.47-4.52 (m, 1H), 5.87 (d, J 2.8 Hz, 1H), 7.32-7.34 (m, 3H), 7.37-7.41 (m, 2H) ¹³C NMR (100 MHz, CD₃OD) δ 22.69, 46.18, 51.92, 64.71, 70.23, 71.26, 77.73, 108.31, 128.37, 129.10, 129.98, 137.53, 147.07, 157.71, 165.34, 174.28 ⁺HRMS (ESI-TOF) calcd for C₁₉H₂₆N₄O₇ [M + H]⁺ 422.1801, found 422.1809.

16b-258

HPLC spectrum of compound 16b-258 (purity 99%)

Column Vydac C18-column (Cat# 218TP54, 4.6mm I.D. *250 mm (5 μ M))

Eluent H₂O (0.1% TFA) / Acetonitrile

	H ₂ O(0.1%TFA)	Acetonitrile	Flow rate (ml min)
0 min	100%	0%	1
10 min	72%	28%	1
15 min	65%	35%	1
20 min	50%	50%	1



#	Time	Area	Height	Width	Area%	Symmetry
1	14.718	126.2	6.8	0.2616	0.250	0.491
2	15.477	301.4	17.3	0.2385	0.597	1.123
3	16.258	50089.2	2251	0.3295	99.153	0.43


Supporting Information

HPLC spectrum of compound **1a** (purity 99%)

Column: Vydac C18-column (Cat# 218TP54, 4.6mm I.D. *250 mm (5 μM))

Eluent: H₂O (0.1% TFA) / Acetonitrile

	H ₂ O(0.1%TFA)	Acetonitrile	Flow rate (ml/min)
0 min	100%	0%	1
10 min	72%	28%	1
15 min	65%	35%	1
20 min	50%	50%	1



#	Time	Area	Height	Width	Area%	Symmetry
1	13.611	293.5	19.2	0.26	0.662	2.889
2	14.107	853.7	132.9	0.0953	1.886	6.63
3	14.325	43620.2	2146.2	0.2939	96.379	0.535
4	19.426	485.7	26.7	0.3033	1.073	0.997


Neuraminidase inhibition assay


Influenza virus A/SN/33 (H1N1) and influenza virus A/Taiwan/3446/2002(H3N2) were kindly provided by Dr. Shin-Ru Shih (The Clinical Virology Laboratory of Chang Gung Memorial Hospital (Linkou, Taoyuan)). As the source of viral neuraminidase stock, large-scale influenza virus suspensions were prepared from MDCK cells infected with influenza virus (MOI 0.01) for 72 hrs. To inactivate viral infectivity, virus suspensions were treated with formaldehyde at a final concentration of 0.01% at 37 °C for 30 min, basically the same as our previous report.^{5,6} Such preparations were safe for handling on the bench because the viral titer is under the detection limit but without decreasing the NA activity. Aliquots of the inactivated


virus supernatants were stored at -80°C . The NA enzymatic activity was measured using the fluorogenic substrate MU-NANA, according to the method of Potier et al.⁷ The viral stock was titrated in two-fold dilutions in 32.5 mM MES (pH 6.0)-4 mM CaCl_2 , and the dilution of NA stock giving rise to approximately 5:1 to 10:1 signal to noise (S/N) ratio was employed in the NA inhibition assays. Fluorometric determinations were quantified with a Fluoroskan spectrofluorometer (Labsystems, Helsinki, Finland) based on the release of the fluorescent product 4-methyl-umbelliferone (4MU) using excitation and emission wavelengths of 360 and 460 nm, respectively. For NA inhibition assays, the appropriate viral NA dilution (10 μl) were preincubated with 10 μl zanamivir derivatives at variable concentrations for 30 min at 37°C in 96-well, and the fluorogenic substrate was added at a final concentration of 100 μM in assay buffer (32.5mM 2-(N-morpholino)-ethanesulfonic acid, 4mM CaCl_2 at pH 6.5) for 1 hour. The enzymatic reaction was terminated by the addition of 150 μL stop solution (25% ethanol, 0.1M glycine, pH 10.7). IC₅₀ determination was performed with GraphPad Prism 4.

References


1. von Itzstein, M.; Wu, J.-J.; Jin, B., *Carbohydr. Res.* **259** (2), 301-305
2. Konno, H.; Kubo, K.; Makabe, H.; Toshiro, E.; Hinoda, N.; Nosaka, K.; Akaï, K., *Tetrahedron* **63**, 9502-9513.
3. Li, J.; Kou, J.; Luo, J.; Fan, E., *Tetrahedron Lett.* **49**, 2761-2763
4. Chang, C.; Pickens, J. C.; Hol, G. J.; Fan, E., *Org. Lett.* **6**, 1377-1380
5. Hung, H.-C.; Tseng, C.-P.; Tang, J.-M.; Ju, J.-J.; Tseng, S.-N.; Chen, C.-F.; Chao, C.-S.; Hsieh, H.-P.; Shih, S.-R.; Hsu, J. T. A., *Antiviral Res.* **81**, 123-131.
6. Hung, H.-C.; Liu, C.-L.; Hsu, J. T. A.; Horng, J.-T.; Fang, M.-J.; Wu, S.-C.; Ueng, S.-H.; Tang, M.-C.; Law, C.-J.; Hou, M.-H., *Anal. Chem.* **84**, 6391-6399.
7. Potier, M.; Mameli, L.; Bissile, M.; Dallaire, L.; Melançon, S. B., *Anal. Biochem.* **24** (2), 287-296.














3b





























3f








3f















3h




























31









31
























30



















3r







































3w















3y











3z








3 aa





















14ad







14ad







14ac







14ae





14af





14af

